Bicara Therapeutics (BCAX) EPS (Weighted Average and Diluted) (2023 - 2026)
Bicara Therapeutics (BCAX) reported EPS (Weighted Average and Diluted) of -$0.93 for Q1 2026, down 36.76% on a YoY basis from -$1.47 in Q1 2025, and down 36.76% quarter-over-quarter from -$0.68 in Q4 2025.
Bicara Therapeutics (BCAX) EPS (Weighted Average and Diluted) (2023 - 2026) Analysis & Trends
Bicara Therapeutics has reported EPS (Weighted Average and Diluted) for 4 years, with the latest figure at -$0.93 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 36.76% year-over-year to -$0.93; the trailing twelve-month figure through Mar 2026 stood at -$2.78 (up 80.24% YoY), and the FY2025 full-year result was -$2.52, up 37.78% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.93, down from -$0.68 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $7.22 in Q4 2024, with the low at -$38.23 in Q3 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$8.5 across 4 years, with a median of -$0.93 in 2026.
- Annual changes were most pronounced in 2024 — EPS (Weighted Average and Diluted) jumped 137.16% — and 2025, when it tumbled 109.42%.
- Bicara Therapeutics' EPS (Weighted Average and Diluted) stood at -$19.43 in 2023, then jumped by 137.16% to $7.22 in 2024, then plunged by 109.42% to -$0.68 in 2025, then sank by 36.76% to -$0.93 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.93 (Q1 2026), -$0.68 (Q4 2025), and -$0.67 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Bicara Therapeutics | 1.41 Bn | 1.41 Bn | - | -0.93 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.93 |
| Dec 31, 2025 | -0.68 |
| Sep 30, 2025 | -0.67 |
| Jun 30, 2025 | -0.50 |
| Mar 31, 2025 | -0.68 |
| Dec 31, 2024 | 7.22 |
| Sep 30, 2024 | -1.60 |
| Jun 30, 2024 | -19.01 |
| Mar 31, 2024 | -18.94 |
| Dec 31, 2023 | -19.43 |
| Sep 30, 2023 | -38.23 |